There have been several reports of propofol becoming extrinsically contaminated with bacteria. These reports have usually related to infusions or delays in administration after the ampoule has been opened. This observational study was performed to examine bacterial contamination of propofol during usual practice in the operating theatres of a single large hospital group.
Propofol (2,6 di-isopropyl phenol) is currently available in a lipid emulsion (2.25% glycerol, 1.2% egg lecithin and 10% soybean oil). This formulation can support bacterial growth. A Medline search on bacterial contamination and propofol use in the operating theatre environment discovered two studies 1,2 , one case report 3 , one editorial 4 and several letters [5] [6] [7] [8] [9] . Practices such as "multidosing", where the contents of a single 20 ml ampoule is used for more than one patient, and "reuse", where the remainder of a syringe is administered towards the end of a case, may be associated with a greater risk of significant contamination. The practice of multidosing of propofol is not recommended by the manufacturers.
The purpose of this study was to determine the incidence of extrinsic contamination of propofol during routine clinical use in the operating theatres at the Mater Misericordiae Public Hospitals and to observe whether there was any relationship between contamination and the practice of multidosing.
METHODS
Approval for the study was obtained from the Director of Anaesthesia, Mater Misericordiae Hospitals.
One hundred samples of propofol 1.0 ml were collected from the remnants of syringes and ampoules immediately after propofol administration. Samples were excluded if they contained any additives. Specimens were collected from cases where the delay between opening the ampoule and administration was greater than 15 minutes. The time from when the ampoule was opened until the propofol was administered was recorded. Ampoules were tested several times if they were administered to several patients. The study was conducted over a three-week period.
The propofol samples were injected into bottles of "fastidious growth broth" directly from the syringe or if the sample was from an ampoule, propofol was aspirated aseptically with a sterile 2 ml syringe and needle and injected into the broth. The injection of samples into the broth was performed by the author who had previously demonstrated a sound collection technique with no evidence of bacterial growth on test samples. The culture bottles were incubated at 37°C for four days. All samples were subsequently plated to determine if bacterial growth had occurred. Cultures were considered positive if there was any evidence of bacterial growth. All positive cultures were terminally subcultured for identification. Quantification of growth was not attempted. The content of the unopened propofol ampoule was assumed to be sterile.
Four patterns of propofol handling were identified and the samples grouped accordingly:
The contents of one propofol ampoule are drawn into a single syringe with the intention of it being used for one patient only (subsequent doses are given from the same syringe).
Multiple patients syringe
The contents of one propofol ampoule are drawn immediately into several syringes with the intention of using each syringe on a separate patient.
Single patient ampoule
An ampoule is opened for the use of a single patient, and each dose is drawn up as required.
Multiple patients ampoule
An ampoule is opened for use in several patients, and each dose is drawn up as required. Data concerning the reasons for the delay in propofol administration and the details of administration technique were not collected.
RESULTS
A total of 100 samples were collected consisting of 28 in group 1, five in group 2, six in group 3 and 61 in group 4. The time between opening the ampoule and administration of the contents ranged from 15 to 210 minutes (Figure 1 ).
There were three positive samples. They all came from group 4 (multiple patient doses drawn up as required from a single ampoule). This is a 4.9% (95% Confidence Interval 1.0 to 13.7) incidence of bacterial growth in this group. The organisms grown were Staphylococcus epidermidis, Pseudomonas aeruginosa and a mixed growth of three organisms. The times between opening the ampoule and drug administration for the positive samples were 50, 60, and 165 minutes.
DISCUSSION
The soya bean emulsion in which propofol is formulated is an ideal environment for promoting bacterial growth 10 . The preparation contains no preservative or antimicrobial agent. There have been several reports of postsurgical infection due to contaminated propofol 1,3-5 . Epidemiological investigations suggest that any contamination of propofol was from an external source 3 advance were suggested as causes 1, 3, 4 . Further correspondence has cast doubt on the scientific validity of the described link 6 .
Our results are in accord with a previous study which found a 6.3% incidence of bacterial contamination of propofol 2 . The number of samples in the four groups was too small to draw any conclusions about their relative safety. It is of interest that all our positive growth samples were derived from group 4 (multiple patient doses drawn up as required from a single ampoule). This technique is most frequently used in paediatric anaesthesia because of the small doses required. It avoids wastage of a relatively expensive drug but review of the technique may be appropriate to minimize the risk of injecting bacterially contaminated propofol. Increasing time between opening the ampoule and administration may make positive culture more likely by providing time for replication of bacterial contaminants and greater opportunity for contamination of the open ampoule.
All samples kept in a syringe after the ampoule was opened were free of bacterial growth. Bench studies suggest that propofol can be aspirated into sterile syringes aseptically and remain bacteria-free for 72 hours 7 . There have been some reports suggesting even up to 14 days can be safe 8, 9, 11 . In each of these studies drawing up protocols were not described. It has been suggested that it may take Staphylococcus aureus more than eight hours to begin to multiply in propofol or intralipid at room temperature 12 . One study showed scant growths of Staphylococcus epidermidis from both propofol and midazolam infusions (mean infusion time 6.9 hours). The authors questioned whether this is of clinical significance, especially as ambient ICU temperatures (20 to 24°C) are much less than the 37°C used in the study 13 .
Staphylococcus epidermidis is the most likely bacteria to be found as a contaminant. The presence of a mixed growth finding and Pseudomonas aeruginosa was surprising. Pseudomonas is a waterborne bacterium. Water splashing from hand washing or pooling on the drug trolley and droplet transmission are possible routes of entry into the open ampoule.
Swabbing the neck of the ampoule of propofol with an alcohol swab prior to opening and drawing up into a syringe may decrease the risk of contamination 14 . A review of the literature suggests that if an ampoule of propofol is opened, drawn up in a "sterile or clean" fashion and kept in a sterile container, the risk of contamination is low. The potentially significant costs, both in morbidity and monetary terms, should the administration of bacterially contaminated propofol produce an adverse patient outcome should be considered when planning for the cost-efficient use of propofol.
On the basis of our results and review of the literature, we suggest the following guidelines to minimize the potential for bacterial contamination of propofol: 1. Propofol should be drawn into a syringe immediately after the ampoule has been opened. 2. It is preferable that propofol be used as soon as possible after the ampoule has been opened. 3. If there is a delay between opening the ampoule and administration then it is suggested that the propofol be stored in a capped syringe. 4. If there is any doubt about the integrity of the propofol then it should be discarded. 5. Consider cleaning the ampoule neck before opening. This study confirms that bacterial contamination of propofol can occur in the operating theatre. All contaminated samples in this study were associated with deviations from the manufacturer's recommended practice (see Appendix). The practice of repeated drawing of doses of propofol from an open ampoule, as is common in paediatric anaesthesia, may be particularly associated with bacterial contamination of propofol.
APPENDIX
Zeneca Pharmaceuticals Australia Pty Ltd recommendations 15 : • For single use only in an individual patient • Contents of ampoule should be drawn up aseptically into a sterile syringe or giving set as soon as seal or ampoule is broken • Administration should commence without delay • Maintenance of asepsis throughout administration period • Propofol should not be administered via a microbiological filter • Added drugs or fluids must be administered close to the cannula site • Syringe, giving set, and any unused portion of propofol must be discarded at the end of the surgical procedure or 12 hours
